Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to learn which sapacitabine treatment is more likely to
keep the cancer in check for at least one year in AML patients who are at least 70 years of
age or older and in MDS patients who are at least 60 years of age.